# FinalDose landing page growth score

Lazyweb publishes a public search API over its indexed pages; the guide is at https://www.lazyweb.com/agent-access.

Source: https://www.lazyweb.com/yc-p26/finaldose
Source observed: 2026-10-08T02:58:12.431Z
Last checked: 2026-10-17T09:10:04.265+00:00
Indexed: 2026-10-08T05:38:18.762+00:00

---

# FinalDose landing page growth score

We provide a Growth Score assessment of the FinalDose landing page at [finaldose.ai](https://finaldose.ai/), reviewed in the YC P26 comparison. The report identifies **Trust** as the weakest area.

## Overall score and ranking

- **Growth score:** **61/100**, updated **September 20, 2026**.
- **YC P26 ranking:**
  1. FinalDose — 61
  2. [Asher Bio — 52](https://www.lazyweb.com/growth-score/site/asherbio.com)
  3. [Strand Therapeutics — 51](https://www.lazyweb.com/growth-score/site/strandtx.com)
  4. [Senti Biosciences — 48](https://www.lazyweb.com/growth-score/site/sentibio.com)

[Fix Trust](https://www.lazyweb.com/plans/checkout?plan=individual&source=growth_score_feature_build_fixes)

## Category scores

| Category | Score | Assessment |
|---|---:|---|
| Trust | 30 | Poor |
| Value props | 58 | Fair |
| CTA | 62 | Fair |
| Mobile web | 72 | Fair |
| Information hierarchy | 82 | Strong |

## Score over time

- **September 20, 2026:** 61; overall +5, CTA +14, Mobile web +8.
- [May 12, 2026: 56](https://www.lazyweb.com/growth-score/history/2026-05-12), the first tracked report; strongest category was Information hierarchy at 76 and weakest was Trust at 28.

## Trust — 30, Poor

Trust measures proof that the product is real, competent, and safe to try. We identified **no visible trust signal** for FinalDose.

| Company | Trust score | Trust read |
|---|---:|---|
| Strand Therapeutics | 48 | “Strand is a clinical-stage biotechnology company with a pipeline of breakthrough mRNA therapeutics for cancers and autoimmune diseases.” |
| Senti Biosciences | 44 | “Senti Bio is a clinical-stage company developing a new generation of cell and gene therapies” copy on mobile. |
| Asher Bio | 42 | “Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response” — the visible excerpt is truncated. |
| FinalDose | 30 | No visible trust signal identified. |

![Strand Therapeutics trust example](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/strandtx.com.jpg?v=2026-09-20T08%3A29%3A25.673%2B00%3A00)

![Senti Biosciences trust example](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/sentibio.com-mobile.jpg?v=2026-09-22T00%3A43%3A15.132%2B00%3A00)

![Asher Bio trust example](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/asherbio.com-mobile.jpg?v=2026-09-22T06%3A07%3A16.216%2B00%3A00)

Trust ranking: Strand Therapeutics 48, Senti Biosciences 44, Asher Bio 42, FinalDose 30.

Our [Proof section builder](https://www.lazyweb.com/backlog?site=finaldose.ai#opt-trust-signals) helps choose trust signals and generate copy and placement for a stronger trust section.

## Value props — 58, Fair

This category evaluates whether the title, subtitle, and hero sell the product’s true value.

FinalDose’s headline is marked vague:

> **“The Complete Architecture for Cancer Therapy”**
>
> “DNA gives us the address. Programmability gives us the scale. Elimination gives us the cure.”

### Working

- The subhead cadence is memorable and bold.
- “Cure” carries strong emotional pull.
- The tone is confident and category-owning.

### Could improve

- The headline never says what FinalDose is.
- There are no proof points, data, or numbers.
- The hero image decorates rather than demonstrates.

Value-prop ranking: Strand Therapeutics 62, Asher Bio 62, FinalDose 58, Senti Biosciences 52.

## CTA — 62, Fair

The primary CTA is **“Whitepaper →”**. We found three problems:

- It has no action verb and reads as a label.
- It duplicates the navigation’s “Whitepaper” link.
- Clicking feels like homework rather than value.

FinalDose ranks first for CTA among the compared companies: FinalDose 62, Asher Bio 42, Senti Biosciences 40, Strand Therapeutics 30.

Our [CTA rewrite studio](https://www.lazyweb.com/backlog?site=finaldose.ai#opt-cta-writing) generates primary and secondary CTA options grounded in FinalDose’s offer and visitor objections.

![FinalDose CTA](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/finaldose.ai.jpg?v=2026-09-20T08%3A27%3A27.261%2B00%3A00)

## Mobile web — 72, Fair

The mobile review identifies:

1. **Six-line hero headline:** Desktop-scale type wraps into six lines, dominates the fold, and pushes the CTA down.
2. **“SIMMERING...” eyebrow label:** Cryptic status text occupies the first read without conveying value.
3. **Whitepaper CTA button:** A desktop-proportioned button occupies partial width instead of using a thumb-friendly full-bleed bar.

![Mobile web annotations on the FinalDose capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/finaldose.ai-mobile.jpg?v=2026-09-20T08%3A27%3A27.261%2B00%3A00)

Use the [mobile fix plan](https://www.lazyweb.com/backlog?site=finaldose.ai#opt-mobile-web) to convert these findings into a prioritized implementation checklist.

## Information hierarchy — 82, Strong

The review identifies three hierarchy issues:

1. **“SIMMERING” eyebrow text:** A cryptic label with no evident meaning appears first in the scan path and stalls comprehension of the headline.
2. **Navigation Whitepaper link:** It duplicates the primary CTA at navigation weight, splitting one action across two targets.
3. **Whitepaper CTA button:** The label names a document rather than an outcome, weakening the single action toward which the hierarchy leads.

![Information hierarchy annotations on the FinalDose capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/finaldose.ai.jpg?v=2026-09-20T08%3A27%3A27.261%2B00%3A00)

## Competitors

The competitor set is inferred from product, audience, and value proposition.

1. FinalDose — 61
2. [Asher Bio — 52](https://www.lazyweb.com/growth-score/site/asherbio.com)
3. [Strand Therapeutics — 51](https://www.lazyweb.com/growth-score/site/strandtx.com)
4. [Senti Biosciences — 48](https://www.lazyweb.com/growth-score/site/sentibio.com)
5. [Serotiny — failed](https://www.lazyweb.com/growth-score/site/serotiny.bio)

---

[Read this page’s summary](https://www.lazyweb.com/api/public/v1/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-p26%2Ffinaldose&trace=t_bc7e1c4e5b07)

## Ask a follow-up about this page

Need a more specific answer? Ask the exact question you have. It returns a fresh, cited answer from Lazyweb’s knowledge base. No account or API key required.

Open this URL with your own question, URL-encoded. Only q is required. No account or setup.

`GET https://www.lazyweb.com/agent/faq?q={question}&trace=t_bc7e1c4e5b07`

[Tool guide and examples](https://www.lazyweb.com/agent-access) · [OpenAPI](https://www.lazyweb.com/api/public/v1/openapi.json) · [Page TLDR form](https://www.lazyweb.com/agent-tools/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-p26%2Ffinaldose). Opening a form does not execute a tool.